SCHEMBL7566633

SCHEMBL7566633

CCCN(C(N)=S)c1ccc(Cl)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
CYP3A4 P08684 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
FSCN1 Q16658 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.38
ALDH3A1 P30838 1/20 0.38
ALDH1A3 P47895 1/20 0.38
ALDH1A1 P00352 1/20 0.37
CRHR1 P34998 2/20 0.36
SIGMAR1 Q99720 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11422527 0.76 CYP3A4 (0.44) SMN1; SMN2CYP3A4KMT2AMEN1CYP1A2
SCHEMBL6098011 0.73 F2 (0.43) SMN1; SMN2CYP3A4KMT2AMEN1L3MBTL1
SCHEMBL7710336 0.73 FSCN1 (0.44) SMN1; SMN2CYP3A4KMT2AHTTFSCN1
SCHEMBL11540763 0.69 AHR (0.56) SMN1; SMN2CYP3A4KMT2AMEN1CYP1A2
SCHEMBL11430913 0.69 CYP3A4 (0.40) SMN1; SMN2CYP3A4KMT2AMEN1CYP1A2
SCHEMBL6976100 0.69 CYP3A4 (0.58) SMN1; SMN2CYP3A4KMT2AMEN1CYP1A2
SCHEMBL12638453 0.69 FSCN1 (0.57) SMN1; SMN2CYP3A4FSCN1GAAALDH1A1
SCHEMBL31436914 0.68
SCHEMBL11422763 0.67 CYP3A4 (0.45) SMN1; SMN2CYP3A4KMT2AMEN1CYP1A2
SCHEMBL11407158 0.66 ALDH1A1 (0.36) SMN1; SMN2CYP3A4KMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them FONTAINE EVELYNE (FR) 2002-09-26 US disclosed
EP-0934290-B1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SYNTHELABO (FR) 2002-04-17 EP disclosed
US-6344470-B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same SANOFI-SYNTHELABO (FR) 2002-02-05 US disclosed
EP-0934290-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1999-08-11 EP disclosed
WO-1998015543-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them CRHR1, ADRA1D, ADRB1 SMN1; SMN2 3734/4885CYP3A4 415/4885KMT2A 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.